GT Biopharma Statistics
Total Valuation
GT Biopharma has a market cap or net worth of $5.93 million. The enterprise value is -$3.85 million.
Market Cap | 5.93M |
Enterprise Value | -3.85M |
Important Dates
The next estimated earnings date is Monday, August 5, 2024, before market open.
Earnings Date | Aug 5, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
GT Biopharma has 2.16 million shares outstanding. The number of shares has increased by 27.50% in one year.
Shares Outstanding | 2.16M |
Shares Change (YoY) | +27.50% |
Shares Change (QoQ) | -0.05% |
Owned by Insiders (%) | 6.67% |
Owned by Institutions (%) | 15.67% |
Float | 1.13M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.12 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.15, with a Debt / Equity ratio of 0.01.
Current Ratio | 2.15 |
Quick Ratio | n/a |
Debt / Equity | 0.01 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -9,635.00 |
Financial Efficiency
Return on equity (ROE) is -111.50% and return on invested capital (ROIC) is -243.39%.
Return on Equity (ROE) | -111.50% |
Return on Assets (ROA) | -66.10% |
Return on Capital (ROIC) | -243.39% |
Revenue Per Employee | n/a |
Profits Per Employee | -$4.82M |
Employee Count | 2 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.14% in the last 52 weeks. The beta is 0.66, so GT Biopharma's price volatility has been lower than the market average.
Beta (5Y) | 0.66 |
52-Week Price Change | -72.14% |
50-Day Moving Average | 3.27 |
200-Day Moving Average | 5.20 |
Relative Strength Index (RSI) | 43.19 |
Average Volume (20 Days) | 52,713 |
Short Selling Information
The latest short interest is 43,008, so 1.99% of the outstanding shares have been sold short.
Short Interest | 43,008 |
Short Previous Month | 32,015 |
Short % of Shares Out | 1.99% |
Short % of Float | 3.82% |
Short Ratio (days to cover) | 0.56 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -13.00M |
Pretax Income | -9.64M |
Net Income | -9.64M |
EBITDA | -9.64M |
EBIT | -9.64M |
Earnings Per Share (EPS) | -$6.98 |
Balance Sheet
The company has $9.81 million in cash and $30,000 in debt, giving a net cash position of $9.78 million or $4.53 per share.
Cash & Cash Equivalents | 9.81M |
Total Debt | 30,000 |
Net Cash | 9.78M |
Net Cash Per Share | $4.53 |
Equity (Book Value) | 5.31M |
Book Value Per Share | 2.46 |
Working Capital | 5.29M |
Cash Flow
Operating Cash Flow | -10.11M |
Capital Expenditures | n/a |
Free Cash Flow | -10.11M |
FCF Per Share | -$7.32 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
GT Biopharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -27.50% |
Shareholder Yield | -27.50% |
Earnings Yield | -162.47% |
FCF Yield | -170.45% |
Analyst Forecast
The average price target for GT Biopharma is $105.00, which is 3,718.18% higher than the current price. The consensus rating is "Buy".
Price Target | $105.00 |
Price Target Difference | 3,718.18% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on February 5, 2024. It was a reverse split with a ratio of 1:30.
Last Split Date | Feb 5, 2024 |
Split Type | Reverse |
Split Ratio | 1:30 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |